NEW DELHI, 27 JUNE 2013: The health ministry has suspended the sale of two drugs - painkiller Analgin and anti-diabetes drug Pioglitazone and all its combinations . While the ban on Analgin in India has come after almost 36 years after the drug was banned in the US (which banned it in 1977), Pioglitazone was pulled out of France in 2011 for an increased risk of bladder cancer. Analgin was withdrawn from Sweden in 1997 for the risk of causing a sharp fall in white blood cells, a potentially fatal condition. It is still being marketed in India, the house panel noted. The drug is also banned in France, Canada, Australia, New Zealand, Japan among a host of other countries. Pioglitazone, howevercontinues to be sold in most other major markets, including the US, the UK, Japan, Canada. The domestic drug industry is protesting the move, saying this ban would force lakhs of patients to move to more expensive alternatives and insulin. "There are over 30 lakh patients using this drug. There is no evidence to show that the drug has caused any adverse drug reactions in India, despite being marketed in the country since 2001," said DG Shah, secretary general, Indian Pharma Alliance. |
Thursday, June 27, 2013
HM bans two drugs Analgin and Pioglitazone
Tuesday, June 25, 2013
NPPA FIXED PRICES OF 40 FORMULATIONS (DATED21/6/2013)
The National Pharmaceutical Pricing Authority has fixed / revised the prices in respect of 40 formulation packs Notification / orders dated 21.6.2013
For details please click the following:
- Copies of Gazette Notifications for Ceiling Prices
Saturday, June 22, 2013
Pharma companies cut prices of top medicines
MUMBAI, 22 JUNE 2013: Prices of widely-used medicines like antiseptic skin lotion Betadine, fever pill Calpol, supplement folvite, antibiotic Azithral, a host of cardiac medication including Ismo, Losar and Repace (Losartan) and anti-diabetic drug Daonil, will be revised downwards. The price reduction comes in the wake of a proposed revision by drug companies in line with ceiling prices notified by the drugs pricing regulator earlier this week. The benefit to patients is an average 25-27%, while the loss to companies in the first round of the policy implementation will be around Rs 920 crore annually. While multinationals like Pfizer and GSK lead the pack of companies most impacted in the first round, others which are hit include Bharat Serums, Win-Medicare, Abbott, Wockhardt, Sun Pharma, Ranbaxy and Zydus Cadila. Pfizer will suffer a loss of Rs 48 crore, followed by Rs 43 crore by GSK on an annual basis, in the first round of implementation of pharma policy. |
Wednesday, June 19, 2013
NPPA FIXED PRICES OF........
The National Pharmaceutical Pricing Authority has fixed / revised the prices in respect of 151 formulation packs Notification / orders dated 14.6.2013
For details please click the following:
NPPA starts notifying new prices of essential drugs as per DPCO 2013
New Delhi, 18 June 2013: The consumers are all set to start getting the benefit of new price regime, as per the Drugs Price Control Order (DPCO) 2013 controlling the prices of essential drugs, by the end of July. In the first batch of revision of prices, according to the National Pharmaceutical Pricing Policy 2012, the National Pharmaceutical Pricing Authority (NPPA) has fixed the prices of 151 formulations that come under the essential drugs to begin the process. |
Monday, June 17, 2013
Prices of key drugs to be cut by up to half
NEW DELHI, 17 JUNE 2013: Some key cancer drugs, antibiotics and medicines to treat cardiovascular diseases and tuberculosis are set to become cheaper by up to 50 per cent within the next 45 days. The National Pharmaceutical Pricing Authority (NPPA) will soon notify prices of as many as 150 packs of essential medicines in line with the new pharma pricing policy, according to official sources. |
Thursday, June 13, 2013
NPPA HAS FIXED/REVISED THE PRICES.....
The National Pharmaceutical Pricing Authority has fixed / revised the prices in respect of 86 formulation packs Notification / orders dated 10.6.2013
For details please click the following:
- Copies of Gazette Notifications for Ceiling and Non-Ceiling Prices
WISH YOU........
Shri N.G.Kulkarni, completed 60 yrs.He is well known supportive,hard and devoted member of both association.He has actively worked for K.C.D.A .Bengaluru.
All the best for his coming service for both the association.
Wednesday, June 12, 2013
NPPA begins process to fix prices of 348 essential drugs as per new DPCO 2013
Mumbai, 12 June 2013: In a move towards fixing the much anticipated ceiling price of the 348 formulations falling under the new Drug Price Control Order (DPCO) 2013, the NPPA last week directed all the state licensing authorities (SLAs) to submit the details of all the manufacturers in their respective states, manufacturing these formulations. |
Subscribe to:
Posts (Atom)